BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account
The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604127/ https://www.ncbi.nlm.nih.gov/pubmed/28943919 http://dx.doi.org/10.3892/ol.2017.6694 |
_version_ | 1783264814366195712 |
---|---|
author | Dong, Si-Yang Zeng, Rui-Chao Jin, Lang-Ping Yang, Fan Zhang, Xiang-Jian Yao, Zhi-Han Zhang, Xiao-Hua Wang, Ou-Chen |
author_facet | Dong, Si-Yang Zeng, Rui-Chao Jin, Lang-Ping Yang, Fan Zhang, Xiang-Jian Yao, Zhi-Han Zhang, Xiao-Hua Wang, Ou-Chen |
author_sort | Dong, Si-Yang |
collection | PubMed |
description | The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC and in different preoperative central lymph node statuses also requires further research. A total of 287 patients with PTC who accepted thyroidectomy were included in the present study. Clinicopathological data of these patients were reviewed to examine the risk factors for central LNM through univariate and multivariate analyses. Overall, BRAF(V600E) in patients with cN0 (subclinical nodal disease) and cN1 (other than cN0) PTC was associated with central LNM. However, multivariate analyses demonstrated that BRAF(V600E) was not an independent risk factor in patients with cN1 or cN0 PTC. For patients with classical variant PTC (CVPTC), BRAF(V600E) was independently associated with central LNM. However, on further analysis, the association was only significant in patients with cN0 CVPTC. For patients with follicular variant PTC (FVPTC) or aggressive variant PTC (AVPTC), the BRAF(V600E) mutation rate was not significantly different between patients with and without central LNM. In conclusion, BRAF(V600E) was an independent risk factor for central LNM overall in patients with PTC and in patients with CVPTC, particularly in patients with cN0 CVPTC. However, BRAF(V600E) was not an independent risk factor for patients with FVPTC and AVPTC. Therefore, BRAF(V600E) provides varied clinical significance in different histological subtypes and preoperative central lymph node status. |
format | Online Article Text |
id | pubmed-5604127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-56041272017-09-22 BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account Dong, Si-Yang Zeng, Rui-Chao Jin, Lang-Ping Yang, Fan Zhang, Xiang-Jian Yao, Zhi-Han Zhang, Xiao-Hua Wang, Ou-Chen Oncol Lett Articles The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC and in different preoperative central lymph node statuses also requires further research. A total of 287 patients with PTC who accepted thyroidectomy were included in the present study. Clinicopathological data of these patients were reviewed to examine the risk factors for central LNM through univariate and multivariate analyses. Overall, BRAF(V600E) in patients with cN0 (subclinical nodal disease) and cN1 (other than cN0) PTC was associated with central LNM. However, multivariate analyses demonstrated that BRAF(V600E) was not an independent risk factor in patients with cN1 or cN0 PTC. For patients with classical variant PTC (CVPTC), BRAF(V600E) was independently associated with central LNM. However, on further analysis, the association was only significant in patients with cN0 CVPTC. For patients with follicular variant PTC (FVPTC) or aggressive variant PTC (AVPTC), the BRAF(V600E) mutation rate was not significantly different between patients with and without central LNM. In conclusion, BRAF(V600E) was an independent risk factor for central LNM overall in patients with PTC and in patients with CVPTC, particularly in patients with cN0 CVPTC. However, BRAF(V600E) was not an independent risk factor for patients with FVPTC and AVPTC. Therefore, BRAF(V600E) provides varied clinical significance in different histological subtypes and preoperative central lymph node status. D.A. Spandidos 2017-10 2017-08-01 /pmc/articles/PMC5604127/ /pubmed/28943919 http://dx.doi.org/10.3892/ol.2017.6694 Text en Copyright: © Dong et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Dong, Si-Yang Zeng, Rui-Chao Jin, Lang-Ping Yang, Fan Zhang, Xiang-Jian Yao, Zhi-Han Zhang, Xiao-Hua Wang, Ou-Chen BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account |
title | BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account |
title_full | BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account |
title_fullStr | BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account |
title_full_unstemmed | BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account |
title_short | BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account |
title_sort | braf(v600e) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: different histological subtypes and preoperative lymph node status should be taken into account |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604127/ https://www.ncbi.nlm.nih.gov/pubmed/28943919 http://dx.doi.org/10.3892/ol.2017.6694 |
work_keys_str_mv | AT dongsiyang brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT zengruichao brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT jinlangping brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT yangfan brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT zhangxiangjian brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT yaozhihan brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT zhangxiaohua brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount AT wangouchen brafv600emutationisnotassociatedwithcentrallymphnodemetastasisinallpatientswithpapillarythyroidcancerdifferenthistologicalsubtypesandpreoperativelymphnodestatusshouldbetakenintoaccount |